TANI, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 1.963
EU - Europa 1.476
AS - Asia 590
AF - Africa 119
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 4.155
Nazione #
US - Stati Uniti d'America 1.951
GB - Regno Unito 429
SE - Svezia 337
VN - Vietnam 219
CN - Cina 192
DE - Germania 166
IT - Italia 160
UA - Ucraina 95
IE - Irlanda 67
IN - India 66
FR - Francia 54
RU - Federazione Russa 45
CI - Costa d'Avorio 39
JO - Giordania 37
SG - Singapore 32
ZA - Sudafrica 32
HR - Croazia 31
TG - Togo 26
EE - Estonia 25
CH - Svizzera 19
JP - Giappone 14
BE - Belgio 12
IR - Iran 12
NG - Nigeria 12
BG - Bulgaria 9
CA - Canada 9
ES - Italia 7
FI - Finlandia 7
SC - Seychelles 6
GR - Grecia 4
TN - Tunisia 4
LB - Libano 3
MX - Messico 3
TR - Turchia 3
TW - Taiwan 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
HK - Hong Kong 2
MY - Malesia 2
NL - Olanda 2
NZ - Nuova Zelanda 2
PL - Polonia 2
RO - Romania 2
AU - Australia 1
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
IL - Israele 1
IQ - Iraq 1
NO - Norvegia 1
SI - Slovenia 1
Totale 4.155
Città #
Southend 382
Fairfield 253
Chandler 219
Houston 165
Ann Arbor 155
Ashburn 133
Woodbridge 132
Seattle 117
Wilmington 107
Cambridge 89
Dong Ket 82
Princeton 76
Dublin 67
Jacksonville 65
Nanjing 42
Abidjan 39
Amman 37
Westminster 36
Turin 35
Padova 34
Lomé 26
New York 26
Berlin 23
Boardman 23
Beijing 21
Singapore 21
Saint Petersburg 19
Jinan 18
Shenyang 16
Changsha 15
Bologna 14
San Diego 14
Nanchang 13
Redwood City 13
Abeokuta 12
Bremen 12
Brussels 12
Jiaxing 12
Bern 11
Milan 11
Florence 10
Mülheim 10
Sofia 9
Hebei 8
Norwalk 8
Tokyo 8
Zhengzhou 8
Dearborn 7
Hangzhou 7
Zanjan 7
Falls Church 6
Helsinki 6
Tianjin 6
Buffalo 5
Izumo 5
Mahé 5
Redmond 5
Taizhou 5
Lausanne 4
Verona 4
Basel 3
Gallarate 3
Haikou 3
Kunming 3
Los Angeles 3
Madrid 3
Mexico 3
Monmouth Junction 3
Ningbo 3
Olalla 3
Rijeka 3
Rome 3
Taipei City 3
Taiyuan 3
Wayne 3
Winnipeg 3
Andover 2
Auckland 2
Barcelona 2
Des Moines 2
Hyderabad 2
Istanbul 2
Leawood 2
London 2
Medford 2
Mountain View 2
Paris 2
Phoenix 2
San Francisco 2
San Giuliano Milanese 2
Amsterdam 1
Baghdad 1
Brindisi 1
Carol Stream 1
Cernusco sul Naviglio 1
Chicago 1
Cupertino 1
Delhi 1
Den Haag 1
Edmonton 1
Totale 2.816
Nome #
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 171
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 166
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 166
18 F-FDG PET in malignant lymphoma: significance of positive findings 160
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 159
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 139
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 137
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 133
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 127
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 118
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 116
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 115
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 112
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 111
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 108
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 108
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 107
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 106
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 105
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 105
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 104
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 104
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 103
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 103
Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. 102
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 102
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 101
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 99
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 98
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 98
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 93
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 90
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 89
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 80
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 76
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 20
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 12
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 9
Totale 4.239
Categoria #
all - tutte 9.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.967


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.176 176 28 13 73 111 143 143 160 154 66 46 63
2020/2021629 108 48 9 22 22 92 5 39 52 30 47 155
2021/2022916 194 21 65 117 57 47 17 48 21 47 180 102
2022/2023948 107 108 54 115 69 84 20 37 211 29 72 42
2023/2024195 13 44 8 27 15 51 5 10 5 8 2 7
2024/202528 28 0 0 0 0 0 0 0 0 0 0 0
Totale 4.239